KYTHERA(R) Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss
September 22, 2015 09:00 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Sept. 22, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced it has submitted an Investigational New Drug Application (IND) to the U.S....
KYTHERA(R) Biopharmaceuticals Submits Marketing Authorization Application in the European Union for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat
August 18, 2015 09:00 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Aug. 18, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) announced today it has submitted a Marketing Authorization Application (MAA) in the...
KYTHERA Biopharmaceuticals Releases Second Quarter 2015 Operating Results and Progress Update
August 06, 2015 16:05 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Aug. 06, 2015 (GLOBE NEWSWIRE) -- Westlake Village, Calif., Aug. 6, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for the...
Allergan and KYTHERA Announce That Pending Transaction Will Now be for All-Cash Consideration
August 05, 2015 08:00 ET
|
KYTHERA Biopharmaceuticals, Inc.
DUBLIN, Ireland and WESTLAKE VILLAGE, Calif., Aug. 05, 2015 (GLOBE NEWSWIRE) -- Allergan plc (NYSE:AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced that they have amended and...
Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan’s Pending Acquisition of KYTHERA
July 27, 2015 17:45 ET
|
KYTHERA Biopharmaceuticals, Inc.
DUBLIN, Ireland and WESTLAKE VILLAGE, Calif., July 27, 2015 (GLOBE NEWSWIRE) -- Allergan plc (NYSE:AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced that the U.S. Federal Trade...
KYTHERA Biopharmaceuticals Announces Health Canada Authorization of BELKYRA(TM), a Submental Contouring Injectable Drug(i)
July 27, 2015 09:00 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., July 27, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced it has received authorization from Health Canada to market BELKYRA™ “for...
KYTHERA Biopharmaceuticals Announces US Availability of KYBELLA(TM) -- First FDA-Approved Injectable Treatment for “Double Chin” -- Through KYBELLA(TM) Trained Physicians
June 19, 2015 09:00 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., June 19, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced the U.S. availability of KYBELLA™ (deoxycholic acid) injection, the first...
Allergan to Acquire KYTHERA Biopharmaceuticals
June 17, 2015 07:00 ET
|
KYTHERA Biopharmaceuticals, Inc.
– Complements Allergan’s Existing Position in Facial Aesthetics – – Lead Product KYBELLA™ the First and Only Approved Non-surgical Treatment for Reduction of Submental Fullness – – Enhances...
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program
June 16, 2015 21:02 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that the Compensation Committee of the Company’s Board of Directors granted...
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program
June 05, 2015 21:40 ET
|
KYTHERA Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., June 05, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that on June 2, 2015, the Compensation Committee of the Company’s Board of...